{"id":"NCT01700192","sponsor":"ALK-Abell√≥ A/S","briefTitle":"Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)","officialTitle":"A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01","primaryCompletion":"2015-04","completion":"2015-04","firstPosted":"2012-10-04","resultsPosted":"2017-03-03","lastUpdate":"2017-09-15"},"enrollment":1482,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Rhinitis, Allergic, Perennial","Rhinitis, Allergic, Nonseasonal"],"interventions":[{"type":"BIOLOGICAL","name":"MK-8237 tablets","otherNames":["SCH 900237"]},{"type":"BIOLOGICAL","name":"Placebo tablets","otherNames":[]},{"type":"DRUG","name":"Rescue Medication: Self-Injectable Epinephrine","otherNames":[]},{"type":"DRUG","name":"Rescue Medication: Loratadine tablets","otherNames":[]},{"type":"DRUG","name":"Rescue Medication: Olopatadine ophthalmic drops","otherNames":[]},{"type":"DRUG","name":"Rescue Medication: Mometasone furoate nasal spray","otherNames":[]}],"arms":[{"label":"MK-8237","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of MK-8237 (SCH 900237) in the treatment of House Dust Mite (HDM)-Induced Allergic Rhinitis/Rhinoconjunctivitis (AR/ARC) in children and adults.\n\nThe primary hypothesis of this study is that administration of MK-8237, compared to placebo, results in significant reduction in the average total combined rhinitis score (TCRS).","primaryOutcome":{"measure":"Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment","timeFrame":"Last 8 weeks of treatment (Weeks 44 to 52)","effectByArm":[{"arm":"MK-8237","deltaMin":4.67,"sd":3.55},{"arm":"Placebo","deltaMin":5.49,"sd":3.82}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":19},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["27521719","36924936","32926419","29656145","29432959"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":743},"commonTop":["Throat irritation","Oral pruritus","Ear pruritus","Nausea","Lip swelling"]}}